# Eli Lilly & Company – FDA 483, Sep 15, 2023

Source: https://www.keypedia.com/records/483/eli-lilly-company/49ac02bf-312b-43ae-96e2-4cf015602e85

> FDA 483 for Eli Lilly & Company on September 15, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Eli Lilly & Company
- Inspection Date: 2023-09-15
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations III
- Summary: Eli Lilly & Company in Indianapolis, IN, received a Form 483 with five observations following an FDA inspection from September 11-15, 2023. The firm failed to adhere to its approved Risk Evaluation and Mitigation Strategy (REMS) for Zyprexa Relprevv, specifically regarding the certification of healthcare providers, pharmacies, and healthcare settings. Additionally, the company did not ensure proper documentation of patient safe-use conditions or timely patient enrollment in the REMS registry, indicating significant non-compliance with drug safety protocols.

## Related Documents

- [483 - 2025-05-20](https://www.keypedia.com/records/483/eli-lilly-company/885fecd9-f6cd-48fd-90eb-66d12ec35d07) — date: May 20, 2025
- [483 - 2023-10-06](https://www.keypedia.com/records/483/eli-lilly-company/f0349542-8a47-4147-9164-7ecacf1fcd4e) — date: October 6, 2023
- [483 - 2023-06-16](https://www.keypedia.com/records/483/eli-lilly-company/ad3d5c22-c165-4f63-91cc-163c31217be2) — date: June 16, 2023
- [EIR - 2023-05-18](https://www.keypedia.com/records/eir/eli-lilly-company/15f9ed35-a475-4557-b1f2-753ea60f17a2) — date: May 18, 2023
- [EIR - 2022-10-21](https://www.keypedia.com/records/eir/eli-lilly-company/a6cfae52-180e-4b9d-9b15-509286f24bc5) — date: October 21, 2022

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/jennifer-a-kemp/51aa8f2f-ba64-47d3-aa06-b4595b3d15c8)
- [investigator](https://www.keypedia.com/people/dina-a-tallman/e9bf2b98-6697-4d7c-9052-84339536acfd)

Company: https://www.keypedia.com/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iii/45bc2d0d-d731-4955-aeb5-59aa0b76e4f0